By Abigail Townsend
Date: Wednesday 29 Apr 2026
(Sharecast News) - GSK posted above-forecast first-quarter profits on Wednesday, boosted by robust demand for its specialist HIV and oncology drugs.
The blue chip pharma saw sales rise 2%, or by 5% on a constant currency basis, to £7.6bn, while core earnings per share came in at 46.5p per share, up...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news